Biogen stock rallies and outperforms rivals

12 articles · Updated · MarketWatch · May 8

Shares rose 1.08% to $193.45 on Friday, marking a fifth straight gain as the S&P 500 climbed 0.84% and the Dow added 0.02%.
Biogen beat peers including Johnson & Johnson, Pfizer and AbbVie, all of which fell during the session.
The stock finished 4.43% below its 52-week high of $202.41 reached on 6 February, while trading volume of 928,505 stayed below its 50-day average.

Biogen's stock is soaring, so why are Wall Street analysts so deeply divided on its future prospects?

With its Alzheimer's drug delayed, can Biogen's $5.6 billion bet on a new acquisition truly secure its future growth?